SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-006377 to CareMax, Inc. (CMAX, CMAXW) (CIK 0001813914)

CareMax, Inc. (CMAX, CMAXW) (CIK 0001813914)
Date: June 14, 2023 · CIK: 0001813914 · Accession: 0000000000-23-006377

AI Filing Summary & Sentiment

Referenced dates: May 15, 2023

Date
June 14, 2023
Author
Not clearly detected
Form
UPLOAD
Company
CareMax, Inc. (CMAX, CMAXW) (CIK 0001813914)

Letter

United States securities and exchange commission logo June 14, 2023 Kevin Wirges Chief Financial Officer and Treasurer CareMax, Inc. 1000 NW 57th Court, Suite 400 Miami, Florida 33126 Re:CareMax, Inc. Form 10-K for the Year Ended December 31, 2022 Form 10-K/A for the Year Ended December 31, 2021 Correspondence Letter dated May 15, 2023 File No. 1-39391 Dear Kevin Wirges: We have reviewed your May 15, 2023 response to our comment letter and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to these comments within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comments apply to your facts and circumstances, please tell us why in your response. After reviewing your response to these comments, we may have additional comments. Unless we note otherwise, our references to prior comments are to comments in our April 20, 2023 letter. Form 10-K for the Year Ended December 31, 2022 Adjusted EBITDA, page 69 1.We note your response to comment 1. In regard to compensation expenses of $4,425,000, which are being adjusted for in your determination of Adjusted EBITDA, please address the following: •Please quantify the amounts associated with stay-on bonuses, severance, and duplicate employees separately; •Discuss how you determined that the expenses excluded are incremental costs and not normal, recurring cash operating expenses necessary to operate your business; •With specific reference to each compensation category (e.g. stay-on bonuses, severance and duplicate employees costs), please more fully explain how the removal

FirstName LastNameKevin Wirges Comapany NameCareMax, Inc. June 14, 2023 Page 2 FirstName LastName Kevin Wirges CareMax, Inc. June 14, 2023 Page 2 of these costs are consistent with Question 100.01 of the Non-GAAP Financial Measures Compliance & Disclosure Interpretations, as updated December 13, 2022. In this regard, we note that these costs appear related to revenue generation; •With regards to stay-on bonuses, please tell us the typical length of time the bonuses commit the employees to stay with the company; and •Specifically tell us the periods over which these types of compensation costs are expected to be incurred. For any costs that extend beyond a year, please further explain how you determined that the adjustment for these costs is appropriate. Refer to Question 100.01 of the Non-GAAP Financial Measures Compliance & Disclosure Interpretations, as updated December 13, 2022. 2.We note your response to comment 3. Please clarify your disclosures in a similar manner to your response. You may contact Nudrat Salik at (202) 551-3692 or Jeanne Baker at (202) 551-3691 if you have any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services

Show Raw Text
United States securities and exchange commission logo
June 14, 2023
Kevin Wirges
Chief Financial Officer and Treasurer
CareMax, Inc.
1000 NW 57th Court, Suite 400
Miami, Florida 33126
Re:CareMax, Inc.
Form 10-K for the Year Ended December 31, 2022
Form 10-K/A for the Year Ended December 31, 2021
Correspondence Letter dated May 15, 2023
File No. 1-39391
Dear Kevin Wirges:
            We have reviewed your May 15, 2023 response to our comment letter and have the
following comments.  In some of our comments, we may ask you to provide us with information
so we may better understand your disclosure.
            Please respond to these comments within ten business days by providing the requested
information or advise us as soon as possible when you will respond.  If you do not believe our
comments apply to your facts and circumstances, please tell us why in your response.
            After reviewing your response to these comments, we may have additional
comments.  Unless we note otherwise, our references to prior comments are to comments in our
April 20, 2023 letter.
Form 10-K for the Year Ended December 31, 2022
Adjusted EBITDA, page 69
1.We note your response to comment 1.  In regard to compensation expenses of $4,425,000,
which are being adjusted for in your determination of Adjusted EBITDA, please address
the following:
•Please quantify the amounts associated with stay-on bonuses, severance, and
duplicate employees separately;
•Discuss how you determined that the expenses excluded are incremental costs and
not normal, recurring cash operating expenses necessary to operate your business;
•With specific reference to each compensation category (e.g. stay-on bonuses,
severance and duplicate employees costs), please more fully explain how the removal

 FirstName LastNameKevin Wirges
 Comapany NameCareMax, Inc.
 June 14, 2023 Page 2
 FirstName LastName
Kevin Wirges
CareMax, Inc.
June 14, 2023
Page 2
of these costs are consistent with Question 100.01 of the Non-GAAP Financial
Measures Compliance & Disclosure Interpretations, as updated December 13, 2022.
In this regard, we note that these costs appear related to revenue generation;
•With regards to stay-on bonuses, please tell us the typical length of time the bonuses
commit the employees to stay with the company; and
•Specifically tell us the periods over which these types of compensation costs are
expected to be incurred.  For any costs that extend beyond a year, please further
explain how you determined that the adjustment for these costs is appropriate.  Refer
to Question 100.01 of the Non-GAAP Financial Measures Compliance & Disclosure
Interpretations, as updated December 13, 2022.
2.We note your response to comment 3.  Please clarify your disclosures in a similar manner
to your response.
            You may contact Nudrat Salik at (202) 551-3692 or Jeanne Baker at (202) 551-3691 if
you have any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services